MedTrace Logo

Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF

NCT06057467 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2351

Last updated 2024-03-18

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the effectiveness between early and late initiation of anticoagulation therapy in acute ischemic stroke (AIS) patients with non-valvular atrial fibrillation (NVAF). Participants will be 1:1 randomized into early or late initiation group. The primary endpoint is early neurological deterioration (END) before discharge.

Conditions

Interventions

DRUG

Anticoagulation Agents

Anticoagulation agents includes rivaroxaban, dabigatran, apixaban, and edoxaban.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2025-10-01
Completion
2026-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06057467 on ClinicalTrials.gov